News Related to Parent Project Muscular Dystrophy

Related coverage linked through entity extraction aliases.

Mesoblast and Satellos advance Duchenne muscular dystrophy treatment trials

Apr 16, 2026

Mesoblast received FDA clearance for a registrational DMD trial of remestemcel-L-rknd, while Satellos began dosing boys in the Phase 2 BASECAMP study of SAT-3247. The studies are enrolling children ages 5-9 and 7-9, respectively.

FDA Grants Fast Track Designation to Precision BioSciences' DMD Gene Therapy

Mar 09, 2026

Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy designed to treat patients with mutations in exons 45-55.